Spotlight on Invent@SC’s Future Biotech Leaders: Meet Seattle Children’s Dr. Edward Song

Founded in 2022, the Invent at Seattle Children’s Postdoctoral Scholars Program is a first-in-the nation postdoctoral training program that aspires to develop novel therapeutics at Seattle Children’s. The program is an investment in training talented early career scientists historically underrepresented in biotech in the development of therapeutics for childhood diseases. It seeks to improve the […]

Read More →

Top 5 Things to Know about Malaria, According to a Seattle Children’s Infectious Disease Researcher

Eight cases of locally acquired malaria have been confirmed in Florida and Texas this summer, marking the first time in 20 years locally transmitted cases have been seen, and decades since malaria was officially eradicated in the United States. Although about 2,000 Americans are diagnosed with malaria each year, those cases are linked with travel […]

Read More →

Seattle Children’s Cancer Leaders Recognized for Continued Efforts to Develop and Discover Better Treatments and Cures

In Seattle Children’s Cancer and Blood Disorders Center (CBDC), patients are treated for some of the most complex and rare conditions seen in children, teens and young adults. Close ties and dual roles between the CBDC care team and Seattle Children’s researchers extends a unique, team approach to treating pediatric patients in their fight against […]

Read More →

Research Highlights: Equity Initiatives Improve Infection Rates; Cell and Gene Therapy Progress; Malaria Study

As one of the nation’s top four pediatric research centers, Seattle Children’s Research Institute remains dedicated to providing hope, care and cures to help every child live the healthiest and most fulfilling life possible. On the Pulse takes a look at some of the highlights from across the research institute over the past month.  

Read More →

Seattle Children’s Lead DIPG Researcher Attends Brain Cancers Forum at The White House

The White House recently convened patients, caregivers, oncologists, researchers and administration officials for the Cancer Moonshot Brain Cancers Forum as the administration moves to advance progress for patients with glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). Among the attendees invited was Dr. Nicholas Vitanza, an attending physician in Seattle Children’s Cancer and Blood Disorders […]

Read More →

Seattle Children’s Trial Medication Stops Emree’s Seizures

It’s been 12 years, but Brandy Epling still chokes up at the traumatic memory of her firstborn’s birth. It was a difficult pregnancy, with preterm labor forcing a 33-day stay at a southwest Washington hospital for the mom-to-be, followed by months of bedrest. Ultrasounds revealed the baby’s brain was a bit bigger on the left […]

Read More →

Seattle Children’s Launches Pioneering Immunotherapy Clinical Trial Targeting Four Antigens at the Same Time to Combat Pediatric Brain and Spinal Cord Tumors

Seattle Children’s Therapeutics has launched BrainChild-04, a first-in-human phase 1 clinical trial that will be our first chimeric antigen receptor (CAR) T-cell clinical trial that targets four antigens at the same time, by delivering CAR T cells directly to the brain. The trial is for children, teens, and young adults with diffuse intrinsic pontine glioma […]

Read More →

Seattle Children’s Therapeutics Marks Milestone Moment in Fight Against Childhood Cancer

Seattle Children’s, an international leader in the effort to better treat cancer in children, teens and young adults by boosting the immune system with immunotherapy, has reached a new milestone by enrolling its 500th patient in its chimeric antigen receptor (CAR) T-cell immunotherapy clinical trials in 10 years. T cells play a key role in […]

Read More →

Seattle Children’s Research Featured in Worldwide Study on COVID-19 Vaccine Safety in Young Children

New findings from Seattle Children’s Research Institute’s Center for Clinical and Translational Research reveal that a three-dose primary series of Pfizer’s COVID-19 vaccine was safe and effective in children 6 months to 4 years of age, even when a new variant (Omicron) was circulating. The findings were released on Feb. 16 in the New England […]

Read More →